News

/News

CURE welcomes new member ReNetX Bio

The mission of ReNetX Bio is to provide first-in-class therapeutics to treat injury/damage to the central nervous system in conditions such as spinal cord injury, stroke, and glaucoma. The company was founded based on technology from Dr. Stephen Strittmatter’s work at Yale University. more

By |December 7th, 2017|News|0 Comments

Cara doses first patient in study of CR845

Cara Therapeuticsreports that it has dosed the first patient in its Phase 1 pharmacokinetic and safety trial of Oral CR845 tablets in patients with stage III-V chronic kidney disease (CKD) who are not on dialysis. "We believe Oral CR845 has the potential to substantially broaden our market potential in patients with CKD-aP," said Derek Chalmers, Ph.D., D.Sc., president and CEO of Cara. more

By |December 7th, 2017|News|0 Comments

Thetis awarded $2.3M NIH grant re bowel disease

Thetis Pharmaceuticals has received a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health. The grant provides up to $2.3 million to support development of Thetis’ TP-317 candidate as oral therapy for treatment of ulcerative colitis. Gary Mathias, Co-founder and Chief Executive Officer, commented: “TP-317 offers a fundamentally new approach to IBD treatment based on active resolution of inflammation and the promotion of tissue regeneration without suppressing the immune system.” more

By |December 7th, 2017|News|0 Comments

Vanessa to begin Phase 2 trials re Shylicine™

Vanessa Research will start its Phase 2 clinical trials in the first quarter of 2018 for the rare disease Microvillus Inclusion Disease (MVID). The primary objective of the Phase 2 clinical trials is to test the clinical activity and efficacy of Shylicine™ for the treatment of diarrhea in MVID. In addition, Vanessa expects to verify the reduction in patient dependency on TPN and register changes in intestinal morphology. more

By |December 7th, 2017|News|0 Comments

Achillion reports progress on flagship drug

Achillion Pharmaceuticals reports that the FDA has granted orphan drug designation to ACH-4471 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Furthermore, the European Medicines Agency Committee for Orphan Medicinal Products has issued a positive opinion on ACH-4471 for orphan status in the European Union for the treatment of PNH ... more Achillion also reports preliminary proof-of-concept results from group 1 of its ongoing Phase 2, open-label, 14-day study of ACH-4471 for patients with C3 glomerulopathy (C3G) or immune complex-mediated membranoproliferative glomerulonephritis ... more Separately, announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder [...]

By |December 7th, 2017|News|0 Comments

Genentech inks $650 M deal with Arvinas

Genentech is doubling down on its commitment to New Haven biotech Arvinas, extending the duo’s partnership and tacking an additional $350 million onto the total deal value. The companies have been working together since 2015, with Genentech licensing Arvinas’ platform for protein degradation Arvinas plans to tag certain disease-causing proteins for destruction by recruiting an E3 ligase to the target, thereby sending the protein to the cell’s natural “garbage disposal” called the ubiquitin-proteasome system. more

By |December 7th, 2017|News|0 Comments

New England Discovery Partners gets STTR grant

Investigators at Yale School of Medicine have teamed up with New England Discovery Partners to develop novel small molecule drugs that combat severe viral disease caused by mosquito-transmitted viruses. The drugs are designed to specifically target those human proteins that the viruses need to successfully establish infection. The drugs will have broad-spectrum activity against multiple medically important flaviviruses including West Nile virus, Dengue virus and Zika virus. This work stems from a multidisciplinary collaboration with expertise in viral genetics, drug discovery, and medicinal chemistry and a team composed of Dr. Joseph Contessa of Yale School of Medicine, Dr. Jan Carette [...]

By |December 7th, 2017|News|0 Comments

Loxo Oncology in billion-dollar deal with Bayer

Loxo Oncology, which is creating medicines for patients with genetically defined cancers, has announced a partnership with pharmaceutical giant Bayer that could be worth more than $1 billion to the Stamford-based firm. Both larotrectinib and Loxo-195, which focus on treating cancers with abnormalities known as “tropomyosin receptor kinase gene fusions,” are under development. The agents have the potential to fulfill the promise of precision medicine, where tumor genetics rather than tumor site of origin define the treatment approach for patients. more

By |December 7th, 2017|News|0 Comments

Cities compete to host EMA after Brexit

Most of the staff of the London-based European Medicines Agency (EMA) would move with the agency if its new host city was Amsterdam, Barcelona, Copenhagen, Milan, or Vienna, according to the results of a staff survey made public on Tuesday (3 October).... more Amsterdam, Barcelona, Brussels and Dublin are among the European cities vying to become the new home of the European Medicines Agency, once the UK leaves Europe ... more

By |December 7th, 2017|News|0 Comments

CURE welcomes new member MEET

MEET helps growth companies and economic development agencies effectively exhibit at trade shows.The company develops strategy, provides staffing, secures speaking opportunities, enrolls prospects, sets appointments, and measures results. more

By |December 7th, 2017|News|0 Comments